Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan

Reuters

2025/06/03

Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan

Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare $(MHLW.SI)$ has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide $(CNP)$ action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540710719"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540710719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540710719?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540710719","market":"nz","top_or_hot":-1,"title":"Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare <a href=\"https://laohu8.com/S/MHLW.SI\">$(MHLW.SI)$</a> has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide <a href=\"https://laohu8.com/S/CNP\">$(CNP)$</a> action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 10:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare <a href=\"https://laohu8.com/S/MHLW.SI\">$(MHLW.SI)$</a> has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide <a href=\"https://laohu8.com/S/CNP\">$(CNP)$</a> action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富蘭克林生物科技新領域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL13HhHw:1","article_id":"2540710719","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540710719","pubTimestamp":1748916665,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare  has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide  action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","ASND":"Ascendis Pharma A/S","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"帝人株式会社宣布孤儿药Navepegritide在日本启动III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":0.9},"content_text":"Teijin Limited Announces Phase III Clinical Trial Launch for Orphan Drug Navepegritide in Japan\n    \n\n        Teijin Pharma Limited has announced that Japan's Ministry of Health, Labor and Welfare $(MHLW.SI)$ has granted Orphan Drug designation to navepegritide for the treatment of achondroplasia, a rare genetic skeletal dysplasia. Developed as TransCon CNP and licensed from Ascendis Pharma, A/S, navepegritide is designed for use in children with achondroplasia in Japan. The drug, which is administered subcutaneously once per week, utilizes TransCon technology to prolong C-type natriuretic peptide $(CNP)$ action. Teijin Pharma plans to initiate a Phase III clinical trial of navepegritide domestically in the first half of fiscal year 2025. Ascendis Pharma has filed a new drug application in the United States and plans to submit a Marketing Authorization application in Europe later in 2025. Achondroplasia affects approximately one in every 20,000 live births and is considered an intractable disease by the MHLW.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}